FDA Approves Abrilada (adalimumab-afzb), a Biosimilar to Humira
FDA Approves Abrilada (adalimumab-afzb), a Biosimilar to Humira Print this page November 18, 2019 – Pfizer Inc. (NYSE: PFE) today announced the United States (U.S.) Food and Drug Administration (FDA) has approved Abrilada™ (adalimumab-afzb), as a biosimilar to Humira® (adalimumab),1 for the treatment of certain patients with rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing… Read More »